Menu

US State Department Names New Science Envoys

The five high-profile scientists are charged with helping strengthen international cooperation.

Jun 13, 2018
Shawna Williams

U.S. DIPLOMACY CENTERFive new science envoys have been named to one-year terms that begin this month, the US Department of State announced last week (June 8). The new appointees, Charles Bolden Jr., Robert Langer, Michael Osterholm, Rebecca Richards-Kortum, and James Schauer, join continuing envoys Margaret Leinen and Thomas Lovejoy.

“It’s a unique opportunity to be involved with countries around the world on specific topics through official government channels,” Osterholm, who directs the University of Minnesota’s Center for Infectious Disease Research and Policy, tells Science Insider. He explains that he plans to work in low- and middle-income countries to tackle antibiotic overuse and bacterial resistance to the drugs.

See “Science Envoy Resigns from US State Department in Protest

The envoys, all prominent leaders in their fields, span a range of specializations. Bolden is a former astronaut and NASA administrator; Langer is an MIT professor focusing on biotechnology and materials science; Richards-Kortum directs the Rice 360º Institute for Global Health at Rice University; and Schauer directs the Wisconsin State Laboratory of Hygiene at the University of Wisconsin-Madison.

See “Oceans’ Ambassador

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.